What this trial studies
This trial investigates whether supervised training in combination with hormonal substitution therapy has an impact on body composition, cardiovascular risk, risk for dementia, osteoporosis and insulin sensitivity in postmenopausal women.
Conditions in scope
- Postmenopause
- Menopausal Complaints
Interventions
- Exercise program (Other) — The intervention consists of a supervised exercise program
- Hormonal substitution therapy per SOC (Drug) — Subjects take hormonal substitution therapy per standard of care
Who can join
Women only · Ages 45 Years to 65 Years
Inclusion criteria
- Postmenopausal women (diagnosed by physician) with complaints due to menopause
- Indication for hormonal substitution therapy (except for the control group)
- Good general health
- BMI: 20-30 kg/m2
- Only the use of cholesterol-, blood pressure- or/and thyroid-regulating medication is permitted
Exclusion criteria
- See ClinicalTrials.gov for full exclusion criteria.
Eligibility wording paraphrased from the public record. View the full criteria on ClinicalTrials.gov before contacting a site.
Where it’s happening
| City | State / Region | Facility | Site status |
|---|---|---|---|
| Ghent | Ghent University Hospital - Women's Clinic | Recruiting |
Status & timeline
- Overall status: Recruiting
- Study type: Interventional
- Phase: N/A
- Start date: 2023-05-12
- Primary completion: 2027-12-31
- Last update posted: 2025-11-18
- First posted: 2023-04-26
Sponsor & contact
Lead sponsor: University Hospital, Ghent (Other)
For trial site contact information, use the official record at ClinicalTrials.gov. Contact details change frequently and the public record is the source of truth.
Outcome measures
Primary outcomes
- Evaluation of the cardiovascular risk (+12 weeks; +24 weeks)
The cardiovascular risk will be estimated by blood- and urine analysis, blood pressure and a AGE (i.e. Advanced Glycation End products)-reader. There are three timepoints of measurement; once at inclusion, once at 12 weeks, and once at 24 weeks. - Evaluation of the insulin sensitivity (+12 weeks, +24 weeks)
The insulin sensitivity will be estimated by blood- and urine analysis and a AGE (i.e. Advanced Glycation End products)-reader. There are three timepoints of measurement; once at inclusion, once at 12 weeks, and once at 24 weeks.
Related ClearedRx care
If you’re reading this trial because you have menopause symptoms now, you don’t have to wait for a trial to access evidence-based care. ClearedRx prescribes the same FDA-approved and compounded HRT products that have been studied in trials like this one for decades.
Important. Information from ClinicalTrials.gov as of May 8, 2026. Trial details (status, sites, contacts, eligibility, outcomes) change frequently — always check the official record at https://clinicaltrials.gov/study/NCT05831709 before contacting a site.
ClearedRx is not affiliated with this trial or its sponsor. We index public-domain ClinicalTrials.gov records to help patients find evidence-based context for menopause care decisions. ClearedRx itself is a telehealth menopause/HRT brand — we do not enroll patients in trials.